Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Inclusion Criteria

• •Inclusion
• •Patients with histologically confirmed metastatic or unresectable solid tumors for which standard curative measures do not exist or are no longer effective; histology will be limited to those tumors for which temsirolimus or vinorelbine have reported clinical activity: lung, breast, ovary, cervix, prostate, uterus, renal, bladder and neuroendocrine tumors
• •SWOG performance status of 0-2
• •Projected life expectancy of at least 3 months
• •Provision of informed consent prior to any study-related procedures
• •Negative pregnancy test for women of childbearing potential
• •Female patients must not be pregnant due to the potential mutagenicity and teratogenicity of this treatment; a pregnancy test must be administered 7 days prior to administration of therapy to women of childbearing potential; patients must agree to use some form of contraception while on this study at initiation and for the duration of participation in the study; sexually active males must also use a reliable and appropriate method of contraception; post-menopausal women must be amenorrheic for at least 12 months to be considered of nonchildbearing potential
• •Patients must have recovered from acute toxicities from previous surgery, chemotherapy or radiation therapy
• •ANC \>= 1500/mm\^3
• •Platelet count \>= 100,000 cells/mm\^3
• •Hemoglobin \>= 9.0g/dL
• •Serum creatinine =\< 1.5 mg/dl
• •Hepatic function: Patients must have adequate liver functions: AST or ALT =\< 2.5 X upper limit of normal (ULN), alkaline phosphatase =\< 2.5 X upper limit of normal; in patients with bone metastasis and no evidence of liver metastasis and bilirubin =\< upper limit of normal an alkaline phosphatase =\< 5 ULN will be allowed
• •Serum Bilirubin =\< 1.0 mg/dL
• •Peripheral neuropathy grade 0-1
• •No other concomitant therapy directed at the cancer is allowed
• •Exclusion
• •Prior therapy with vinorelbine or an mTor inhibitor
• •Receipt of any investigational agents within 30 days prior to commencing study treatment
• •Last dose of prior chemotherapy discontinued less than 4 weeks before the start of study therapy
• •Last radiation therapy within the last 4 weeks before the start of study therapy, except palliative radiotherapy
• •Any unresolved toxicity greater than CTC grade 1 from previous anticancer therapy, excluding alopecia
• •CTC Grade 1 or greater neuropathy (motor or sensory) at study entry
• •Hematologic function with absolute neutrophils =\< 1500/mm\^3 and/or platelets \< 100,000/mm\^3
• •Hepatic function with serum bilirubin greater than the upper institutional limits of normal, ALT and AST \> 2.5 times the upper institutional limits of normal
• •Concurrent use of strong inhibitors of CYP3A4: ketoconazole, itraconazole, ritonavir, amprenavir, indinavir, nelfinavir, delavirdine and voriconazole
• •CYP3A4 inducers should be avoided or used with caution; the use of these agents is discouraged: rifabutin, rifampicin, rifapentine, carbamazepine, Phenobarbital, phenytoin and St. John's wart
• •Ongoing long term use of steroids for chronic conditions